Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Osteosarcoma 4Neuroblastoma 3Sarcoma, Ewing 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Medulloblastoma 1Leiomyosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Bone Neoplasms 1

Interventions

Ibandronic Acid 8Gemcitabine 8Doxorubicin 6Cyclophosphamide 6Zoledronic Acid 5Radiation 4Nivolumab 4Irinotecan 4pembrolizumab 3Vincristine 3Temozolomide 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Docetaxel 3Denosumab 3Cisplatin 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3regorafenib 2pegfilgrastim 2Tranexamic Acid 2Trabectedin 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Quality of Life 2Proton Therapy 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × dinutuximab × Sarcoma × Clear all
NCT06669013 2024-11-01

FollowTheDIN

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Recruiting
40 enrolled
Sarcoma

Bone Neoplasms, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡